For patrons
One gene, one child, and now a funding problem, not a biology problem.
Early money here is worth the most it will ever be. It de-risks the science at the exact moment it turned, and it buys the infrastructure that every future disease branch reuses. Here is who is asking, the leverage, the model, the ask, and the honest risks.
Who is asking, and why to trust it
I am Misha's father, and I run computational research pipelines for a living. This foundation exists because the standard rare-disease path is too slow for my son's hearing, and because the part of the science that used to be impossible just got cheap. You get empathy and competence in one person, with a clock running, and a standing promise to show you the failures next to the wins.
Why a solvable problem stays stuck
The external problem
STRC / DFNB16 has zero approved therapies, and not one lab in Asia is working on it. It is common enough to matter and rare enough for pharma to skip.
The internal problem
A parent is handed the diagnosis and told, gently, to wait. Wait for research no one is funding on your timeline. That helplessness is the real output of the current system.
The deeper problem
Rare diseases die in the gap between a promising result and a fundable program, even when the biology is ready. That gap is a choice, not a law of nature. It is exactly what catalytic capital is for.
The plan, in three moves
Model it before funding it
Rank the hypotheses and predict the structures in silico, so wet-lab money goes to the best shot, not the first guess.
Seed the lab that can move
A 50k to 150k grant buys the preliminary data a lab needs to win the grant that is otherwise out of reach.
Recycle the leverage
Each seed that unlocks a large grant, and each tool shared open-access, lowers the cost of the next disease. The infrastructure outlasts the first cure.
The leverage, and why now
This is the number a venture-philanthropy donor actually cares about. Small early capital buys the data that unlocks capital ten to fifty times larger.
follow-on capital per seed grant
a 50k to 150k grant buys the preliminary data that unlocks the 5M to 50M grant which would not fund without it
And the science just turned. In 2026, a dual-AAV gene therapy restored hearing to near-normal thresholds in a mouse model of this exact gene. The target is no longer hypothetical. This is a funding problem now, not a biology problem.
The leverage compounds past one disease. The pipeline, the registry, and the fundraising model are built once and reused for every case a family ambassador brings. Your capital does not fund one gene. It funds the infrastructure that goes after the next hundred.
Computation got cheap where it counts
AlphaFold has released 214 million-plus predicted structures and won the 2024 Nobel Prize in Chemistry. The expensive, slow part of early structural biology is now hours of inference. Rare disease, being 72% genetic, is the case this helps most.
Nature 2024; Nobel Prize 2024; Nguengang Wakap 2020
Capital already believes it
Recursion raised a 436M dollar IPO explicitly to advance a rare-disease pipeline. insitro raised a 400M dollar round at a 2.4B valuation. Isomorphic Labs, the DeepMind spinout, raised 600M and signed pharma deals worth up to 3B. Computation compressing biology is a funded thesis, not a hope.
Bloomberg 2021; SynBioBeta 2021; TechCrunch 2025
Registries are now trial-grade
The FDA has guidance on natural-history data as an external control arm, which is how tiny populations run rigorous trials. RARE-X already federates 80-plus advocacy groups across 57 disease communities. The plumbing exists. Nobody has pointed it at rare hearing genetics from Asia.
FDA 2019; RARE-X
The model has paid off before
Parent-founded, technical foundations have repeatedly turned small early capital into approved therapies and, in one case, into billions recycled back into research. This is the template.
Cystic Fibrosis Foundation
Royalty Pharma, 2014
Invested about 150M dollars over 15 years into the research that became Kalydeco. In 2014 it sold the royalty rights to Royalty Pharma for 3.3 billion dollars, then poured it back into the field. Vertex's CF therapies now reach roughly 90% of patients, up from about 5%.
Rett Syndrome Research Trust
reverserett.org
Family-funded, roughly 94 cents of every dollar into research, about 92M dollars deployed since 2008. The gene-therapy programs now in Rett clinical trials were incubated at the trust before industry picked them up.
Usher 1F Collaborative
Foundation evolution playbook
Seed grants of 50k to 100k let a university lab pivot into Usher 1F, which unlocked 1.2M dollars from the NIH and a disease foundation. This is the exact structure we are copying for our own first seed grant.
The size of the thing
The business model, on one screen
The whole thing in the Ash Maurya format, read as an impact model rather than a profit one. Unique value in the middle, because that is the part that has to be true.
Problem
More than 7,000 rare diseases, around 300 million people, and fewer than 5% have an approved treatment. Each disease is too small for pharma to chase alone, so research stays fragmented and duplicated. For STRC hearing loss specifically: zero approved therapies, and not one lab in Asia working on it.
Customer segments
Beneficiaries: families with rare genetic disease, starting with STRC / DFNB16. Funders: patrons and family offices in Asia, plus disease grantmakers such as CZI Rare As One, HMRF, and Croucher. Partners: the labs that receive the seed grants.
Unique value
An independent AI lab that de-risks the science with computation before spending wet-lab money, run by a parent with a clock running, publishing everything in public. One rare disease is rare. All rare diseases are not. Shared infrastructure, not one-off charity.
Solution
Four programs. Research Lab (AlphaFold3, hypothesis ranking, open-access). Patient Registry (RARE-X federated, family-controlled, extensible). Grants Program (seed grants sized to unlock 10 to 50x follow-on). Families (community, and the honest signal on priorities).
Channels
Warm-introduction patron outreach in year one. The public wiki as the credibility engine. Disease-grant applications from year two. Individual giving once the brand exists. A small annual gathering later.
Revenue model
A Hong Kong company limited by guarantee, with Section 88 tax-deductible status pending, plus a US fiscal sponsor (about 5 to 7% fee) so US donors get a receipt. Seed patrons now. Grants and individual giving compounding later.
Cost structure
Lean by design. HK incorporation runs about HKD 4,000 to 7,000. The mandatory annual audit is HKD 5,000 to 15,000. A year-one registry costs 12k to 22k US dollars, near zero on a free platform. The first grant is 50k to 150k. One founder, no salary before Section 88. Most of every dollar moves to the bench.
Key metrics
Registry families enrolled. Seed-to-follow-on leverage ratio. Grants disbursed. Open research outputs published. Patron capital committed against target. We publish the real numbers, including the ones that disappoint.
Unfair advantage
Hong Kong as the bridge between Mainland trial pipelines and Western lab quality. Direct lines into the small field of labs moving cochlear gene therapy from mice toward humans. And a founder who runs computational pipelines and has personal urgency that no committee can manufacture.
In plain terms: a computationally-run, parent-driven foundation, positioned in Hong Kong, that de-risks rare-hearing-genetics research before it funds it, and publishes everything, including the failures. The first dollars buy the incorporation, the registry, and the first seed grant. Every dollar after that is meant to leave behind a tool the whole field can use.
The ask, and what it buys
Year one targets 100k to 300k US dollars. Concretely, that funds:
- The HK company and its Section 88 filing, plus the US fiscal-sponsor channel for US donors
- The RARE-X registry live, with the first families enrolled and IRB approval
- The first seed grant, 50k to 150k, to a partner lab for STRC mouse-model and vector work
- The open research outputs, hypothesis ranking and the AlphaFold3 structural set, published on the wiki
Honest note. These year-one and year-three targets are ambitious next to the comparable foundations' organic curves. CureSHANK reached about 547k dollars of annual revenue by year three, STXBP1 about 342k, Usher 1F about 157k. We hit our numbers only if a major patron or a large grant lands early. We will publish the real figures as they come in, including the gap.
The multi-year plan
Targets, not promises. Budget and headcount scale only with the capital and the milestones.
What could go wrong
You should hear it from me.
- Single-founder key-person risk. Today the foundation is one person wearing every hat.
- Scientific relationships are early and not yet formalized. We do not name partners publicly until they sign.
- The year-one to year-three targets are aggressive against the comparable foundations' real curves.
- Therapy timing is not guaranteed to beat Misha's biological window. That is the honest, disclosed founder bias.
- Scope risk. The foundation must outlast Misha's specific cure, which is why it spans sensorineural genetics and rare disease broadly, not one variant.
Sources (6)
- Nguengang Wakap S, et al. European Journal of Human Genetics, 2020.
- The National Economic Burden of Rare Disease Study. EveryLife Foundation, 2021.
- Orphan Drug Market sizing. Towards Healthcare, 2025; Precedence Research.
- DiMasi JA, et al. Cost of drug development. Tufts CSDD, 2014.
- Royalty Pharma / CF Foundation $3.3B royalty transaction, 2014.
- Rare Diseases: Natural History Studies for Drug Development. FDA, 2019.
The cost of waiting is a childhood.
Cochlear development does not pause for funding cycles. If this is yours to fund, the earliest dollars matter most, and they matter now. If you are not ready to write a check, take a twenty-minute call. I answer every email myself, and I will show you the work behind every number on this page.